Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Rybrevant Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0201

    Rybrevant (amivantamab-vmjw), Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) Coverage Criteria

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0201 alerts

    Get alerted when Policy CC-0201 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit coverage and prior authorization for amivantamab-vmjw and amivantamab/hyaluronidase-lpuj in adults and individuals under 19 with specified recurrent, advanced, locally advanced, or metastatic non-small cell lung cancer. Coverage requires the applicable EGFR mutation, disease status, prior-treatment history, and combination or single-agent regimen described in the criteria.

    Policy Summary
    PayerEmpire Bluecross
    PolicyRybrevant and Rybrevant Faspro coverage criteria
    Policy CodePolicy CC-0201
    Change TypeModified
    Effective DateJune 23, 2026
    Last ReviewMay 15, 2026
    Next Review DateNot scheduled
    Key ActionSubmit requests for clinical review and prior authorization against the medical-necessity criteria in this policy.
    SourceLink
    POLICY UPDATE CHANGES

    The criteria now refer to progression on amivantamab in any formulation and clarify disease progression on or after EGFR tyrosine kinase inhibitor treatment.

    The policy added a step-therapy requirement for Rybrevant Faspro.

    The policy revised coding by removing HCPCS C9999 and J9999 for Rybrevant Faspro and adding HCPCS J9062.

    The policy added coverage criteria for Rybrevant and Rybrevant Faspro in NSCLC with brain metastases.

    2Covered drug formulations

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4
    FDA-approved NSCLC indication pathways summarized
    3Required molecular alterations
    3HCPCS treatment codes listed
    Brain metastasesAdditional covered disease presentation

    Covered Indications and Treatment Pathways

    Covered Indications and Treatment Pathways

    Requests for Rybrevant (amivantamab-vmjw) or Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) may be approved when <strong>ANY</strong> of the following pathways is met:

    ANY of the following

    • Individual is under 19 years of age.
    • ALL of the following

      • Individual has a diagnosis of recurrent, advanced, or metastatic non-small cell lung cancer (NSCLC) (Label, NCCN 2A).
      • Lung cancer has epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
      • Individual has disease progression on or after platinum-based chemotherapy.
      • Individual has not progressed on prior therapy with amivantamab (any formulation).
      • Individual is using as a single agent.
    • ALL of the following

      • Individual has a diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) (Label, NCCN 1).
      • Lung cancer has epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
      • Individual is using as first-line therapy in combination with carboplatin and pemetrexed.
    • ALL of the following

      • Individual has a diagnosis of recurrent, advanced, or metastatic non-small cell lung cancer (NSCLC) (Label, NCCN 1).
      • Lung cancer has epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R mutations.
      • Individual is using as subsequent therapy in combination with carboplatin and pemetrexed.
      • Individual has had disease progression on or after treatment with an EGFR tyrosine kinase inhibitor (e.g. osimertinib).
    • ALL of the following

      • Individual has a diagnosis of recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC) (Label, NCCN 1, 2A).
      • Lung cancer has epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations.
      • ANY of the following uses

        • Individual is using in combination with lazertinib as first-line therapy.
        • Individual is using in combination with lazertinib as continuation of therapy following disease progression on amivantamab (any formulation) and lazertinib.
        • Individual is using in combination with lazertinib as subsequent therapy following disease progression on osimertinib for symptomatic systemic disease with multiple lesions.
    • ALL of the following

      • Individual has a diagnosis of central nervous system cancer (NCCN 2A).
      • Individual has a primary diagnosis of non-small cell lung cancer (NSCLC), and disease has metastasized to the brain.
      • Cancer has epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation.
      • ANY of the following uses

        • Individual is using in combination with lazertinib.
        • Individual is using in combination with carboplatin and pemetrexed.

    Requests for Rybrevant (amivantamab-vmjw) or Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) may not be approved if the criteria above are not met, including for all indications not included above.

    Billing and Diagnosis Codes

    HCPCSHCPCS
    J9061Injection, amivantamab-vmjw, 2 mg [Rybrevant]
    J9062Injection, amivantamab 5 mg and hyaluronidase-lpuj [Rybrevant Faspro]
    ICD-10 DiagnosisICD-10
    C33Malignant neoplasm of trachea
    C34.00-C34.92Malignant neoplasm of bronchus and lung
    C79.31Secondary malignant neoplasm of brain

    Authorization, Sequencing, and Denial Conditions

    Prior Authorization

    Clinical Review and Prior Authorization Required

    Requests for Rybrevant or Rybrevant Faspro are subject to clinical review under the member’s medical benefit, including prior authorization, to determine whether applicable medical-necessity criteria are met.

    • Submit documentation supporting the patient’s age, diagnosis, EGFR mutation, disease extent, prior therapies and progression history, and the requested regimen.
    • Coverage may be considered for an individual under 19 years of age or when one of the policy’s specified NSCLC indications and treatment combinations is met.
    Step Therapy

    Required Prior Therapy and Progression

    Treatment sequencing and documented disease progression are required for applicable indications. The request must also identify the applicable NSCLC diagnosis, EGFR mutation, disease setting, and combination or single-agent regimen.

    • For EGFR exon 20 insertion NSCLC treated as a single agent, the disease must have progressed on or after platinum-based chemotherapy, with no progression on prior amivantamab in any formulation.

    Therapy Overview

    Amivantamab is a bispecific monoclonal antibody directed against the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) receptor. It is available as Rybrevant (amivantamab-vmjw, intravenous formulation) and Rybrevant Faspro (amivantamab with hyaluronidase-lpuj, subcutaneous formulation). These products are used for selected locally advanced, recurrent, or metastatic non-small cell lung cancer involving specified EGFR mutations, including exon 19 deletion, exon 21 L858R, or exon 20 insertion mutations.

    Clinical Terms

    First-line therapy
    DefinitionThe first or primary treatment for the diagnosis.
    Possible treatmentMay include surgery, chemotherapy, radiation therapy, or a combination of these therapies.
    Treatment positionFirst-line therapy is the initial treatment in the line of therapy.
    Second-line therapy
    DefinitionTreatment given when initial treatment, or first-line therapy, is not effective or there is disease progression.
    Prior treatmentFollows initial or first-line treatment.
    Applicable circumstance

    Initial and First-Line Therapy

    Initial and First-Line Therapy

    Initial therapy may be covered when one of the following first-line treatment pathways is met, including the applicable mutation and disease-status requirements.

    Initial and first-line pathways

    • EGFR exon 20 insertion NSCLC

      • Individual has locally advanced or metastatic non-small cell lung cancer (NSCLC).
      • Lung cancer has an epidermal growth factor receptor (EGFR) exon 20 insertion mutation.
      • Treatment is used as first-line therapy in combination with carboplatin and pemetrexed.
    • EGFR exon 19 deletion or exon 21 L858R NSCLC

    Continuation and Subsequent Therapy

    Continuation and Subsequent Therapy

    Continuation or subsequent therapy may be covered when the applicable EGFR mutation, disease status, prior-treatment progression, and regimen requirements are met.

    Continuation and subsequent therapy pathways

    • Continuation after amivantamab and lazertinib

      • Individual has recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC).
      • Lung cancer has an EGFR exon 19 deletion or exon 21 L858R substitution mutation.
      • Treatment is used in combination with lazertinib.
      • Disease has progressed on amivantamab in any formulation and lazertinib.

    Required Treatment Sequencing

    Treatment pathwayRequired prior therapy or progressionTreatment sequencing requirement
    EGFR exon 20 insertion NSCLC — single-agent therapyDisease progression on or after platinum-based chemotherapy; no progression on prior amivantamab in any formulation.Rybrevant or Rybrevant Faspro must be used as a single agent after the required prior therapy.
    EGFR exon 19 deletion or exon 21 L858R NSCLC — subsequent combination therapyDisease progression on or after treatment with an EGFR tyrosine kinase inhibitor, such as osimertinib.Use as subsequent therapy in combination with carboplatin and pemetrexed.
    EGFR exon 19 deletion or exon 21 L858R NSCLC — lazertinib combinationFor continuation: disease progression on amivantamab and lazertinib. For subsequent therapy: progression on osimertinib for symptomatic systemic disease with multiple lesions, or progression on carboplatin or cisplatin/​​osimertinib/pemetrexed when not previously given.Use in combination with lazertinib as first-line therapy, continuation, or the applicable subsequent-therapy setting.
    Policy Summary
    PayerEmpire Bluecross
    PolicyRybrevant and Rybrevant Faspro coverage criteria
    Policy CodePolicy CC-0201
    Change TypeModified
    Effective DateJune 23, 2026
    Last ReviewMay 15, 2026
    Next Review DateNot scheduled
    Key ActionSubmit requests for clinical review and prior authorization against the medical-necessity criteria in this policy.
    SourceLink
    On This Page
    Covered Indications and Treatment PathwaysBilling and Diagnosis CodesAuthorization, Sequencing, and Denial ConditionsTherapy OverviewClinical TermsInitial and First-Line TherapyContinuation and Subsequent TherapyRequired Treatment Sequencing
    Individual is using in combination with lazertinib as subsequent therapy if progression on carboplatin or cisplatin/osimertinib/pemetrexed if not previously given.
  1. For EGFR exon 19 deletion or exon 21 L858R NSCLC treated subsequently with carboplatin and pemetrexed, the patient must have progressed on or after an EGFR tyrosine kinase inhibitor, such as osimertinib.
  2. For exon 19 deletion or exon 21 L858R disease treated with lazertinib, permitted sequencing includes continuation after progression on amivantamab plus lazertinib, subsequent therapy after osimertinib for symptomatic systemic disease with multiple lesions, or progression on carboplatin or cisplatin/osimertinib/pemetrexed when the regimen was not previously given.
  3. First-line regimens and other covered combinations must follow the policy: exon 20 insertion NSCLC with carboplatin and pemetrexed; exon 19 deletion or exon 21 L858R NSCLC with lazertinib; or eligible central nervous system NSCLC with brain metastases using lazertinib or carboplatin and pemetrexed.
  4. Denial Risk

    Criteria or Indication Not Met

    A request may not be approved when the applicable clinical criteria are not met or when the requested use is outside the indications and treatment combinations specified in this policy.

    • Verify the diagnosis, disease setting, EGFR mutation, treatment line, required combination, and any applicable prior-therapy or progression requirement before submission.
    • Non-covered examples include an indication not listed in the policy, failure to document the required mutation or disease characteristics, failure to document required progression or prior therapy, or use of an unlisted regimen.
    Step Therapy

    Single-Agent Sequencing Requirement

    Single-agent Rybrevant or Rybrevant Faspro requires recurrent, advanced, or metastatic NSCLC with an EGFR exon 20 insertion mutation and documented disease progression on or after platinum-based chemotherapy.

    • The patient must not have progressed on prior therapy with amivantamab in any formulation.
    • Single-agent use must be distinguished from the policy’s combination regimens, including combinations with carboplatin and pemetrexed or lazertinib.
    May be used when the initial treatment does not work or the disease progresses.
    Third-line therapy
    DefinitionTreatment given when both initial treatment and subsequent treatment are not effective or there is disease progression.
    Prior treatmentsFollows both first-line therapy and second-line therapy.
    Applicable circumstanceMay be used when both earlier treatments do not work or the disease progresses.
    Metastasis
    DefinitionThe spread of cancer from one part of the body to another.
    Tumor characteristicA metastatic tumor contains cells like those in the original, or primary, tumor.
    Spread locationCancer may spread from the original tumor to another part of the body.
    Monoclonal antibody
    DefinitionA protein developed in the laboratory.
    Binding functionCan locate and bind to specific substances in the body.
    Cancer-cell targetCan bind to specific substances on the surface of cancer cells.
    Progressive disease
    DefinitionCancer that is growing, spreading, or getting worse.
    GrowthThe cancer may be increasing or becoming more extensive.
    Clinical statusThe disease is worsening rather than remaining controlled or improving.
    Refractory disease
    DefinitionIllness or disease that does not respond to treatment.
    Treatment responseThe disease remains unresponsive to the treatment provided.
    Clinical meaningThe condition is resistant to the treatment being used.
    Relapse or recurrence
    DefinitionThe return of signs and symptoms of illness or disease after a period of improvement.
    Prior disease statusThe period of improvement is one during which the disease could not be detected.
    Cancer locationFor cancer, it may return at the original primary tumor site or in another place in the body.
    Individual has recurrent, locally advanced, or metastatic NSCLC.
  5. Lung cancer has an EGFR exon 19 deletion or exon 21 L858R substitution mutation.
  6. Treatment is used in combination with lazertinib as first-line therapy.
  7. NSCLC with brain metastases

    • Individual has central nervous system cancer.
    • Individual has a primary diagnosis of NSCLC and the disease has metastasized to the brain.
    • Cancer has an EGFR exon 19 deletion or exon 21 L858R substitution mutation.
    • Combination regimen

      • Treatment is used in combination with lazertinib.
      • Treatment is used in combination with carboplatin and pemetrexed.
  8. Subsequent therapy after osimertinib

    • Individual has recurrent, locally advanced, or metastatic NSCLC.
    • Lung cancer has an EGFR exon 19 deletion or exon 21 L858R substitution mutation.
    • Treatment is used in combination with lazertinib.
    • Disease has progressed on osimertinib for symptomatic systemic disease with multiple lesions.
  9. Subsequent therapy after platinum-based osimertinib and pemetrexed

    • Individual has recurrent, locally advanced, or metastatic NSCLC.
    • Lung cancer has an EGFR exon 19 deletion or exon 21 L858R substitution mutation.
    • Treatment is used in combination with lazertinib.
    • Disease has progressed on carboplatin or cisplatin/Osimertinib/pemetrexed, and the regimen was not previously given.
  10. Subsequent combination therapy after an EGFR tyrosine kinase inhibitor

    • Individual has recurrent, advanced, or metastatic NSCLC.
    • Lung cancer has an EGFR exon 19 deletion or exon 21 L858R mutation.
    • Treatment is used as subsequent therapy in combination with carboplatin and pemetrexed.
    • Disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor, such as osimertinib.